Acta Scientific Cancer Biology

EditorialVolume 1 Issue 1

Mutation or Methylation?

Pilar Eroles*

INCLIVA Health Research Institute, Spain

*Corresponding Author: Pilar Eroles, INCLIVA Health Research Institute, Spain.

Received: June 05, 2017; Published: July 03, 2017

Citation: Pilar Eroles. “Mutation or Methylation?”. Acta Scientific Cancer Biology 1.1 (2018).

  Among the alterations involved in cancer, modifications in genes related to the cell cycle, proliferation, and apoptosis pathways are common. The majority of work evaluates germline or somatic genetic mutations which occur directly in the DNA sequence, while far less work has been done to analyse changes that do not modify DNA sequences themselves but rather, examine dysregulated epigenetic factors, such as modifications in histones, microRNAs, and DNA methylation.

  DNA methylation plays several critical roles in gene regulatory processes. One clear example of the importance of methylation is that of the breast cancer 1/2 (BRCA1/2) genes. These tumour suppressor genes play an essential part in the homologous recombination (HR) system.

Copyright: © 2018 Pilar Eroles. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Member In



News and Events


  • Submission Timeline for Regular Issue
    The last date for submission of articles for regular Issues is November 25, 2019.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US